Bioheart Inc.

Bioheart has an exclusive license to patents covering the culturing of myogenic cells such as myoblasts, for the purpose of muscle regeneration. The company's goal is a cell therapy that uses autologous myocytes to replace damaged heart muscle cells, potentially offering a therapy that can reverse the course of congestive heart failure.

Coronary artery disease is a relatively new phenomenon—at least from the standpoint of evolution—and human beings are ill-equipped to combat it. Unlike cells in the body's other types of muscle tissues, heart muscle cells that die as a result of a heart attack or other disease aren't naturally replaced, because cardiocytes don't replicate. Damaged heart tissue can ultimately trigger the cascade that leads to the pathological enlargement of the heart as it tries to compensate for damage; patients suffering these symptoms eventually join the ranks of the 11 million people worldwide that suffer from congestive heart failure (CHF).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business